Sage Journals: Discover world-class research

Retricted access

Research article

First published 2021-3

Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri ® Observational Program (TOP)

Helmut Butzkueven, Maria Trojano, Ludwig Kappos [...]

Multiple Sclerosis Journal

Retricted access

Research article

First published 2011-2

An approach to natalizumab hypersensitivity: a case series of induction of tolerance

Marie Camacho-Halili, Roxanne George, Malcolm Gottesman [...]

Multiple Sclerosis Journal

Retricted access

Research article

First published 2021-4

Real-world disability improvement in patients with relapsing–remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program

Heinz Wiendl, Tim Spelman, Helmut Butzkueven [...]

Multiple Sclerosis Journal

Open access

Research article

First published 2021

No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score–matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP)

Helmut Butzkueven, Ludwig Kappos, Tim Spelman [...]

Therapeutic Advances in Neurological Disorders

Open access

Research article

First published 2019

The societal impact of treatment with natalizumab of relapsing–remitting multiple sclerosis in Italian clinical practice: The Tysabri ® PharmacoEconomics (TyPE) Study

B Polistena, F Spandonaro, R Capra [...]

Global & Regional Health Technology Assessment: Italian;Northern Europe and Spanish

Retricted access

Case report

First published 2015-5

Transfer of Natalizumab into Breast Milk in a Mother with Multiple Sclerosis

Teresa E. Baker, Shaun D. Cooper, Lacy Kessler [...]

Journal of Human Lactation

Open access

Review article

First published 2012

New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come

J. Nicholas, B. Morgan-Followell, D. Pitt [...]

Journal of Central Nervous System Disease

Open access

Research article

First published 2020-1

Duration of natalizumab therapy and reasons for discontinuation in a multiple sclerosis population

Devon S Conway, Carrie M Hersh, Haleigh C Harris [...]

Multiple Sclerosis Journal – Experimental,Translational and Clinical

Retricted access

Research article

First published 2012-10

Prediction of antibody persistency from antibody titres to natalizumab

Poul Erik H Jensen, Nils Koch-Henriksen, Finn Sellebjerg [...]

Multiple Sclerosis Journal

Open access

Research article

First published 2026

Natalizumab for pediatric multiple sclerosis: a systematic review and meta-analysis

Yasin Ebne-Ali-Heydari, Aryana Ramezani, Amirmohammad Jozayi [...]

Therapeutic Advances in Neurological Disorders

Search results